Arcus Biosciences (RCUS) Preferred Stock Liabilities (2016 - 2017)
Arcus Biosciences' quarterly Preferred Stock Liabilities came in at $226.2 million in Q4 2017, up 89.36% year-on-year from $119.5 million in Q4 2016, and up 89.36% quarter-over-quarter from $119.5 million in Q4 2016.
Arcus Biosciences has reported Preferred Stock Liabilities for 2 years, with the latest figure at $226.2 million in Q4 2017.
- For the quarter ending Q4 2017, Preferred Stock Liabilities rose 89.36% year-over-year to $226.2 million; the trailing twelve-month figure through Dec 2017 stood at $226.2 million (up 89.36% YoY), and the FY2017 full-year result was $226.2 million, up 89.36% from the prior year.
- Preferred Stock Liabilities for Q4 2017 stood at $226.2 million, up from $119.5 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $226.2 million in Q4 2017, with the low at $119.5 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 226.20 Mn |
| Dec 31, 2016 | 119.45 Mn |